U.S. pharma large copyright scrapped two experimental weight loss products last year—a at the time-everyday capsule, lotiglipron, on account of elevated liver enzymes and a twice-daily pill, danuglipron, because of sturdy Unwanted side effects—but CEO Albert Bourla has said the company is decided to “Engage in and gain” within the obesity H